BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
SMED is a company benefiting from a huge one-time sales and earnings surge, with no reason to believe the March-Dec '09 performance will be repeated. Back in Feb. '09 SMED got a contract from "an agency of the US Government" (in their SEC filings they strangely do not give any more clarity on exactly which agency the contract was from.) The contract's value is ostensibly $40 million dollars, but the last 9 million of it is subject to the unnamed gov't agency picking up an option to continue working with SMED through a "maintenance" program for the units the gov't purchased in the first year of the program. Note the timing of the revenues from this contract: $28.5 million in year one (which is the revenue you currently see in SMED's results ended 12/31/09), $1.6 million in year two (the year we are entering now) and an optional $3 million each year in years 3, 4, and 5 should the unnamed gov't agency pick up the option.
So, the surge in revenues you see in the trailing 12 month numbers are one-time in nature, and we are about to enter a period where revenue will decline about 60% next year, before accounting for any growth outside of this government contract. Outside of this single gov't contract, SMED has limited history of growth in its operations, though recently the H1N1 flu season resulted in a spike (of about $1 million) in their retail segment, which sells disposal equipment to pharmacies. Although their investor presentations trumpet the massive growth quite prominently, as you can see below, growth excluding the one-time revenue surge from the government contract is substantially more subdued.
If you consider the business prospects outside of the government contract, you'll find a company whose stock assumes some pretty substantial growth prospects, growth that SMED has not been able to realize to date. I think SMED probably has about $1-2 million in pre-tax earnings power outside of the 1-time contract, even with a 20x multiple attached to that earnings stream (to assume substantial growth prospects) and an assumed $25 million cash balance from the profits of the gov't contract, leaves the stock worth only about $3 - $5.
For the Last 12 Months Ending
12/07 03/08 06/08 09/08 12/08 03/09 06/09 09/09 12/09
Revenue 12.9 13.0 12.8 13.7 13.3 16.4 20.3 31.4 44.0
Gov't contract - - - - - 2.9 6.1 17.1 28.6
Revenue ex Gov't contract 12.9 13.0 12.8 13.7 13.3 13.5 14.2 14.3 15.4
Revenue Growth 3.2% 26.4% 58.1% 128.9% 230.0%
Revenue growth ex-Gov't contract 3.2% 4.0% 10.6% 4.3% 15.6%
From the recent 10-Q:
On February 2, 2009, the Company announced a $40 million contract award (the “U.S. Government Contract”) to provide its Sharps®MWMS™ to an agency of the United States Government. The total contract is expected to be executed over a five year period (one year plus four option years). On February 1, 2009, The Company received a purchase order for $28.5 million which represents products and services to be provided during the first contract year of which $6.0 million was billed, in aggregate, in the quarters ended March 31, and June 30, 2009, $11.0 million in the quarter ended September 30, 2009 and $11.5 million related to the U.S. Government Contract in the quarter ending December 31, 2009. In January 2010, Sharps was awarded the first option year (ending January 31, 2011) valued at $1.6 million and will be realized from February 1, 2010 through January 31, 2011. The remaining three option years are expected to be approximately $3 million per year as the program moves from the production phase to the maintenance phase. The above amounts are estimates only and are subject to change. Although the Company believes the amounts above to be reasonable based upon its current project plan, it makes no assurances regarding the actual recognition of revenue by fiscal year, which could vary significantly from that noted above.
You're right regarding the government contract. I certainly had to go back and read their latest earnings release after seeing your pitch. Still, I think the company could generate $0.50 per share in earnings while in maintenance mode on the contract, plus have potential upside from additional contract wins. At $0.50 per share in earnings, the company is priced at 16x earnings at $8.00 per share without considering the potential for new contract wins.
Interested to hear how you get to 0.50 cents per share earnings power. 0.50 cents is 7 million dollars. At 30% tax rate (probably low) that's 10 million pre-tax earnings. At 48% EBIT margin (equivalent to their margins in 2009 inclusive of the huge lump sum from Feds, outside of that period EBIT margins clocked in anywhere from -15% to +15%) that would imply $23 million in sales. If you assume they will get the $3 million in sales from the Federal contract's maintenance period, you would be banking on 30% revenue growth (like for like on ex-contract revenues) for a company that has never achieved above 15% revenue growth (again, assuming this federal contract is a 1x event.) Even if you believed that was possible, do you think you'd want to characterize that achievement as something they can get to in normal course of business... plus have potential upside from **additional** contract wins?
To my mind, 0.50 cents earnings for SMED assumes some pretty great success already. Sure they may achieve it, you never know what rabbits they might pull out of their hat, but the stock is priced as if all of those maybes are in the bag. I can't see how that's a good risk/reward.
-ER
After taking a closer look at this, I think you’re right. Here’s the last 6 quarters:
Quarter – Revenue – Earnings – Earn/Shr
2Q 10 -$15,985M – $5,617M – $0.38 ($11.7M in gov’t revenue)
1Q 10 -$15,379M – $5,819M – $0.40 ($11.0M in gov’t revenue)
Q4 09 – $6,687M – $677M – $0.05 ($3.2M in gov’t revenue)
Q3 09 – $5,971M – $1,330M – $0.10 ($3.0M in gov’t revenue, $654M in income tax benefit)
Q2 09 – $4,270M – $605M – $0.04 ($77k in gov’t revenue)
If we assume that government billings fall to maintenance levels of $750,000/qtr, a quarterly income statement looks like this:
Revenue: $4.8 MM
Gross Profit: $1.7M (35% gross margin)
SG&A: ~$2MM
Net Income: -0.32M
All of this assumes no new contract wins to offset the decline in revenues. Also assumes nothing comes of the following that was noted in the earnings release:
-5 year Federal Supply schedule contract by GSA
-Distribution & Pricing Agreement with Defense Supply Center
-VA Pilot Program
-Pharma manufacturer contracts ($25MM in revenue potential among 15 manufacturers)
There is still a lot of potential here, but I think the baseline is closer to break-even. I was looking at the quarter with the tax benefit and annualizing that number. Big mistake without digging deeper. Before I looked closer, I was thinking odds of 60/40 that this company takes off. Now I’m thinking more like 30/70. Probably not good odds, but it is a very speculative investment. I’m glad I don’t have a larger position.